Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.alembicpharmaceuticals.com | |
Market Cap | 10,307.77 Cr. | |
Enterprise Value(EV) | 10,970.22 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 11.44 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 45.84 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 30.86 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 277.23 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 1.89 | Calculated using Price: 524.40 |
Dividend Yield | 1.91 | Period Ending 2022-03 |
No. of Shares Subscribed | 19.66 Cr. | 196,563,124 Shares |
FaceValue | 2 | |
Company Profile | ||
The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments. |
1 Day |
|
-0.74% |
1 Week |
|
-3.32% |
1 Month |
|
-6.82% |
3 Month |
|
-15.73% |
6 Month |
|
-21.21% |
1 Year |
|
-30.60% |
2 Year |
|
-44.15% |
5 Year |
|
-4.08% |
10 Year |
|
+606.28% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 39.97 | 36.24 | 58.02 | 23.25 | 20.42 | 24.00 | 26.97 | 26.91 | 10.01 | |
Return on Capital Employed (%) | 43.54 | 37.54 | 65.86 | 28.87 | 22.15 | 22.66 | 23.30 | 26.28 | 11.16 | |
Return on Assets (%) | 18.79 | 18.76 | 33.75 | 14.97 | 12.25 | 13.15 | 14.64 | 17.22 | 7.27 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 676 | 885 | 1,597 | 1,902 | 2,220 | 2,719 | 3,219 | 5,067 | 5,238 | 5,120 | |
Non Curr. Liab. | 94 | 72 | 84 | 94 | 576 | 570 | 1,047 | 361 | 162 | 145 | |
Curr. Liab. | 603 | 684 | 944 | 814 | 1,267 | 1,664 | 1,752 | 1,533 | 1,831 | 1,818 | |
Minority Int. | 0 | 0 | -1 | -29 | |||||||
Equity & Liab. | 1,372 | 1,641 | 2,626 | 2,811 | 4,064 | 4,952 | 5,989 | 6,961 | 7,230 | 7,083 | |
Non Curr. Assets | 516 | 750 | 917 | 1,317 | 2,116 | 2,820 | 3,526 | 4,057 | 4,255 | 4,253 | |
Curr. Assets | 857 | 891 | 1,708 | 1,494 | 1,948 | 2,132 | 2,463 | 2,904 | 2,975 | 2,829 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 1,372 | 1,641 | 2,626 | 2,811 | 4,064 | 4,952 | 5,989 | 6,961 | 7,230 | 7,083 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 1,863 | 2,056 | 3,166 | 3,135 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,662 | |
Other Income | 4 | 12 | 9 | 3 | 35 | 27 | 14 | 87 | 50 | 12 | |
Total Income | 1,868 | 2,068 | 3,175 | 3,137 | 3,166 | 3,962 | 4,620 | 5,481 | 5,356 | 5,674 | |
Total Expenditure | -1,506 | -1,661 | -2,161 | -2,520 | -2,516 | -3,079 | -3,392 | -3,913 | -4,432 | -5,006 | |
PBIDT | 362 | 407 | 1,014 | 617 | 650 | 883 | 1,228 | 1,568 | 925 | 668 | |
Interest | -10 | -4 | -5 | -5 | -3 | -18 | -27 | -16 | -18 | -43 | |
Depreciation | -40 | -44 | -72 | -83 | -105 | -115 | -157 | -183 | -287 | -324 | |
Taxation | -75 | -76 | -216 | -122 | -120 | -157 | -199 | -253 | -104 | -47 | |
Exceptional Items | -44 | ||||||||||
PAT | 236 | 283 | 720 | 407 | 421 | 593 | 801 | 1,115 | 516 | 254 | |
Minority Interest | 0 | 0 | 1 | 28 | 5 | ||||||
Share Associate | 0 | -4 | -8 | -9 | 0 | 32 | 5 | -34 | |||
Other Related Items | |||||||||||
Consolidated Net Profit | 236 | 283 | 720 | 403 | 413 | 584 | 829 | 1,147 | 521 | 225 | |
Adjusted EPS | 12 | 15 | 38 | 21 | 22 | 31 | 44 | 58 | 27 | 11 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 265 | 240 | 172 | 948 | 329 | 312 | 812 | 449 | 1,463 | 552 | |
Cash Fr. Inv. | -67 | -81 | -256 | -307 | -486 | -884 | -756 | -732 | -839 | -372 | |
Cash Fr. Finan. | -229 | -151 | 87 | -224 | -129 | 503 | 59 | 155 | -597 | -217 | |
Net Change | -31 | 8 | 3 | 417 | -286 | -69 | 115 | -128 | 27 | -37 | |
Cash & Cash Eqvt | 16 | 24 | 27 | 439 | 153 | 84 | 199 | 72 | 98 | 61 |
Wed, 08 Feb 2023
Analysts/Institutional Investor Meet/Con. Call Updates
|
|
Thu, 02 Feb 2023
Analysts/Institutional Investor Meet/Con. Call Updates
|
|
Thu, 02 Feb 2023
Appointment
|
Wed, 08 Feb 2023 |
|
|
|
|
|